Forging a position as an innovative player in
infectious disease vaccines and therapies

Home
About
Our Technology
Business Development
- Partner Network
- Licensing Strategy and Available Licenses
Investor Relations
Contact Us
- Corporate directory

BioDiem » » BioDiem Half-year Financial Report – 31 December 2018

BioDiem Half-year Financial Report – 31 December 2018 March 20, 2019 • Category • Author Name

Half-year Financial Report – 31 December 2018

Latest News

EOFY 2021 Information

September 22, 2021

Highlights: • LAIV flu vaccine royalty receipt • Progress in Opal’s bid to secure lease to GSK Boronia manufacturing plant • EOFY 2021 share price information Read the full annoucement

Read More
Board changes

September 8, 2021

Announcement of Board Changes

Read More

Join our email list!

Join our email distribution list to be updated with announcements.

© Copyright 2014 BioDiem

Privacy Policy
Terms and conditions